journal article·2018-10-31Open access

Improved anticancer effects of epigallocatechin gallate using RGD-containing nanostructured lipid carriers

Hamed Hajipour, Hamed Hamishehkar, Saeed Nazari Soltan Ahmad, Siamak Barghi, Nazila Fathi Maroufi, Ramezan Ali Taheri

Abstract

The global burden of cancer have encouraged oncologists to develop novel strategies for treatment. Present study was proposed to develop Arginyl-glycyl-aspartic acid (RGD)-containing nanostructured lipid carriers (NLC) as a delivery system for improving the anticancer capability of epigallocatechin gallate (EGCG) on breast cancer cell line by attaching to integrin superfamily on cancer cells. For this purpose, RGD-containing EGCG-loaded NLC were prepared by hot homogenization technique and characterized by different techniques. Then, cytotoxic and apoptotic effects of prepared nanoparticles and their uptake into cells was evaluated. As results, the nanoparticles with particle size of 85 nm, zeta potential of -21 mV, encapsulation of 83% were prepared. Cytotoxicity and apoptosis experiments demonstrated that EGCG-loaded NLC-RGD possessed greatest apoptotic activity. Furthermore, it has been shown that, EGCG-loaded NLC-RGD causes cell cycle arresting more effective than EGCG. Therefore, loading EGCG into NLC-RGD make it more effective in both targeting and accumulation into tumour cells, which results from specialized uptake mechanism by adhesion to αvβ3 integrin. The results strengthen our hope that loading EGCG into RGD-containing NLC could possibly overcome the therapeutic limitations of EGCG and make it more effective in cancer therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Tea Polyphenols and Effects · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Student Research Committee and Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences

Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences

Drug Applied Research Center, Tabriz University of Medical Sciences

Department of Biochemistry and Clinical Laboratories, Faculty of Medical Sciences, Tabriz University of Medical Sciences

Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences

References (44)

Show source-provided references
1. 10.1248/bpb.b12-0110210.1248/bpb.b12-01102 ↗
2. 10.1016/j.canep.2009.10.00310.1016/j.canep.2009.10.003 ↗
3. Vella N, Aiello M, Russo AE, et al. ‘Genetic profiling’and ovarian cancer therapy (review). Molecular Med Rep. 2011;4:771–777.
4. Barghi S, Amiri M, Hajipour H, et al. The effect of dietary constituents on regulation of epigenetic changes in cancer. J Babol Univ Med Sci. 2017;19:63–71.
5. 10.1080/01635581.2012.66151410.1080/01635581.2012.661514 ↗
6. 10.1007/s10456-012-9299-410.1007/s10456-012-9299-4 ↗
7. 10.1042/BJ2011183710.1042/BJ20111837 ↗
8. Hajipour H, Hamishehkar H, Raeisi S, et al. Epigallocatechin-3-gallate induces apoptosis through up-regulation of bax and down-regulation of Bcl-2 in prostate cancer cell line. Int J Med Lab. 2016;3:262–269.
9. 10.1016/S0167-4889(01)00175-610.1016/S0167-4889(01)00175-6 ↗
10. 10.1124/dmd.30.11.124610.1124/dmd.30.11.1246 ↗
11. 10.1093/ajcn/81.1.230S10.1093/ajcn/81.1.230S ↗
12. 10.2217/nnm.10.10110.2217/nnm.10.101 ↗
13. 10.1080/21691401.2017.129064610.1080/21691401.2017.1290646 ↗
14. 10.1016/j.jlumin.2017.08.03210.1016/j.jlumin.2017.08.032 ↗
15. 10.1016/j.ifset.2013.03.00210.1016/j.ifset.2013.03.002 ↗
16. 10.1517/1742524080271259010.1517/17425240802712590 ↗
17. 10.1002/adma.20120083210.1002/adma.201200832 ↗
18. 10.1021/nl404391r10.1021/nl404391r ↗
19. 10.1128/JVI.00868-0810.1128/JVI.00868-08 ↗
20. 10.1038/nrc274810.1038/nrc2748 ↗
21. 10.3389/fonc.2013.0022210.3389/fonc.2013.00222 ↗
22. Cao Y, Zhou Y, Zhuang Q, et al. Anti-tumor effect of RGD modified PTX loaded liposome on prostatic cancer. Int J Clin Exp Med. 2015;8:12182.
23. 10.3322/caac.2126210.3322/caac.21262 ↗
24. 10.1039/C4RA12276C10.1039/C4RA12276C ↗
25. 10.1002/adfm.20140462910.1002/adfm.201404629 ↗
26. 10.1016/j.ijpharm.2012.03.03210.1016/j.ijpharm.2012.03.032 ↗
27. 10.1016/j.colsurfb.2013.03.03910.1016/j.colsurfb.2013.03.039 ↗
28. 10.1016/j.ejps.2014.04.00910.1016/j.ejps.2014.04.009 ↗
29. 10.1002/ijc.2287910.1002/ijc.22879 ↗
30. 10.1007/s10549-010-1293-110.1007/s10549-010-1293-1 ↗
31. 10.1073/pnas.98.4.185310.1073/pnas.98.4.1853 ↗
32. 10.1158/0008-5472.CAN-06-365410.1158/0008-5472.CAN-06-3654 ↗
33. 10.1021/mp800218q10.1021/mp800218q ↗
34. 10.1016/S0169-409X(00)00131-910.1016/S0169-409X(00)00131-9 ↗
35. 10.1016/j.phymed.2010.01.00110.1016/j.phymed.2010.01.001 ↗
36. 10.1016/j.ijpharm.2005.05.02710.1016/j.ijpharm.2005.05.027 ↗
37. 10.1016/j.colsurfb.2011.06.02010.1016/j.colsurfb.2011.06.020 ↗
38. 10.1016/j.canlet.2010.04.01210.1016/j.canlet.2010.04.012 ↗
39. 10.2353/ajpath.2010.10033010.2353/ajpath.2010.100330 ↗
40. 10.1186/bcr247310.1186/bcr2473 ↗
41. 10.1186/1471-2407-7-8010.1186/1471-2407-7-80 ↗
42. Zu Y, Yuan S, Zhao X, et al. Preparation, activity and targeting ability evaluation in vitro on folate mediated epigallocatechin-3-gallate albumin nanoparticles. Yao Xue Xue Bao = Acta Pharmaceutica Sinica 2009;44:525–531.
43. 10.1016/j.nano.2014.05.00710.1016/j.nano.2014.05.007 ↗
44. 10.1002/adhm.20120000610.1002/adhm.201200006 ↗